FY2026/7 Q2 (Interim) Consolidated Financial Results Supplementary Materials
March 23, 2026 Pharma Foods International Co., Ltd
[Disclaimer]
Forward-looking statements in this document, including forecasts, outlooks, and strategies, are based on information
available to the Group at the time of preparation and are not historical facts. We do not guarantee their accuracy. Actual results may differ materially due to changes in the economic or business environment.
Executive Summary
-
Strategic upfront investments driving H1 FY2026 performance
Upfront investments executed per plan; H1 designated as an aggressive investment phase, with H2
positioned for profit transition.
Improved profitability achieved through enhanced retention rates and Lifetime Value (LTV), despite moderate challenges in new customer acquisition.
-
Upward revision of FY2026 full-year earnings forecast
Operating income projected to exceed initial forecasts by 33.3%, driven by increased profitability centered on the flagship "Newmo" series.
H2 focus remains on new value creation, further margin expansion, and strengthening the financial foundation.
-
Redefining "New Value Creation 1K Project"
Core objective remains the enhancement of corporate value. High profitability to be realized through business base reinforcement and capital efficiency, linking innovation-led transformation to high growth. Goal set as becoming a high-profit, high-growth entity rooted in biotechnology. The ¥100 billion revenue target reaffirmed as a key milestone, with project management prioritized on maximizing shareholder and corporate value.
Consolidated Financial Results: FY2026/7 Q2 (Interim)
- Revised Consolidated Forecast
FY2026/7 Q2 (Interim) Consolidated Financial Results Overview
Upfront investments executed as planned, with H1 designated as an aggressive investment phase and H2 as a profit transition period. Interim losses were incorporated into the full-year budget, with a return to profitability expected on a full-year basis. Net income for the current period is projected to increase by 307% year-on-year.
(Millions of Yen)
Net Sales | FY25/7 Interim (Cumulative) 29,857 | FY26/7 Interim (Cumulative) | Change | |
32,441 | +2,583 | +8.7% | ||
Gross Profit | 24,285 | 26,296 | +2,010 | +8.3% |
Operating Profit | 623 | ▲2,361 | -2,984 | - |
Ordinary Profit | 645 | ▲2,437 | -3,083 | - |
Net Income Attributable to Owners of Parent | 229 | ▲1,824 | -2,054 | - |
Interim Consolidated Cash Flows
Assets, Liabilities, Net Assets, and Cash Flows
Funding for growth investments secured per business plan. Total liabilities increased by ¥1,382 million from the
previous fiscal year-end due to higher interest-bearing debt. Operating cash flow and financial position projected
to improve following the profit transition in H2.
(Millions of Yen)
+1,854 7,586
-538
Acquisition of Non-
current assets
Planned upfront
investment in BtoC
End of FY25/7 | End of FY26/1 | Change | ||
Total Assets | 32,649 | 32,255 | -393 | |
Current Assets | 23,870 | 22,345 | -1,524 | |
PP&E | 4,696 | 4,837 | +141 | |
Other | 4,082 | 5,071 | +989 | |
Total Liabilities | 21,101 | 22,484 | +1,382 | |
Current Liabilities | 20,005 | 21,666 | +1,661 | |
Non-current Liabilities | 1,096 | 817 | -279 | |
Total Shareholders' Equity | 11,353 | 9,351 | -2,002 | |
9,057 -2,782
(Millions of Yen)
Securing funds for growth
investment
Net Assets | 11,547 | 9,771 | -1,776 |
Equity Ratio | 35.4% | 30.3% | -5.1points |
Interest-bearing Debt Balance | 12,661 | 14,878 | +2,217 |
D/E Ratio (multiple) | 1.09 | 1.52 | +0.43points |
Beginning Balance
Operating CF
Investing
CF
Financing CF
Ending
Balance*
*including effect of exchange rate changes on cash and cash equivalents
©︎Pharma Foods International co., Ltd.